Indian Journal of Medical and Paediatric Oncology

LinksSchließen

Referenz

Jackisch C, Stroyakovskiy D, Pivot X. et al
Subcutaneous vs intravenous trastuzumab for patients with ERBB2-positive early breast cancer: final analysis of the HannaH phase 3 randomized clinical trial.

JAMA Oncol 2019;
5 (05) e190339

Bibliographische Angaben herunterladen

Aufrufen in: